MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.24 6.9

Buy Sell

Overview

Share price change

24h

Current

Min

1.15

Max

1.23

Key metrics
By Trading Economics
Income	-124K -32M
Sales	-372K 1.4M
EPS	-0.27
Profit margin	-2,364.792
Employees	161
EBITDA	-13M -42M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+99.12% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-43M 131M
Previous open	-5.66
Previous close	1.24

News Sentiment

By Acuity

54%

46%

288 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 mar 2026, 23:31 UTC

Hot Stocks

Stocks to Watch: Nike, RH, NCino

31 mar 2026, 22:35 UTC

Earnings

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 kwi 2026, 00:00 UTC

Acquisitions, Mergers, Takeovers

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mar 2026, 23:50 UTC

Acquisitions, Mergers, Takeovers

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mar 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mar 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mar 2026, 23:21 UTC

Earnings

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mar 2026, 23:14 UTC

Market Talk

Earnings

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mar 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Loss Widens >000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mar 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mar 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mar 2026, 21:35 UTC

Earnings

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Earnings

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Earnings

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mar 2026, 21:33 UTC

Acquisitions, Mergers, Takeovers

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar 2026, 21:33 UTC

Earnings

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mar 2026, 21:32 UTC

Earnings

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mar 2026, 21:28 UTC

Earnings

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mar 2026, 21:26 UTC

Earnings

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mar 2026, 21:25 UTC

Earnings

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mar 2026, 21:24 UTC

Market Talk

Earnings

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mar 2026, 21:22 UTC

Earnings

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mar 2026, 21:22 UTC

Earnings

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mar 2026, 21:21 UTC

Earnings

Nike's Digital Channel Still Too Promotional, CFO Says

31 mar 2026, 21:20 UTC

Earnings

Nike CEO: Converse Remains Important to Portfolio

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

99.12% upside

12 Months Forecast

Average 2.25 USD 99.12%

High 2.5 USD

Low 2 USD

Based on 4 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

288 / 349 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.